Get the Stockscreener App
66.75
3.42%
2.21
After Hours:
66.75
Ptc Therapeutics Inc stock is traded at $66.75, with a volume of 684.78K.
It is up +3.42% in the last 24 hours and down -1.49% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
See More
Previous Close:
$64.54
Open:
$65.24
24h Volume:
684.78K
Relative Volume:
0.55
Market Cap:
$5.53B
Revenue:
$1.73B
Net Income/Loss:
$682.64M
P/E Ratio:
8.628
EPS:
7.7364
Net Cash Flow:
$411.18M
1W Performance:
-0.37%
1M Performance:
-1.49%
6M Performance:
+15.40%
1Y Performance:
+18.62%
1-Day Range:
$64.88
$67.45
1-Week Range:
$64.00
$69.02
52-Week Range:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
66.75 | 5.34B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics Appoints Jessica Chutter To Board - citybiz
PTC Therapeutics Adds Veteran Banker to Board - TipRanks
Ptc Therapeutics appoints biotech banking pioneer Jessica Chutter to board of directors - marketscreener.com
PTC Therapeutics, Inc. Appoints Jessica Chutter to Board of Directors - marketscreener.com
PTC Therapeutics appoints Jessica Chutter to its board - TradingView
Biotech banker Jessica Chutter joins PTC Therapeutics (NASDAQ: PTCT) board - Stock Titan
PTC Therapeutics adds Jessica Chutter to board of directors - Investing.com
Morgan Stanley biotech banker tied to $80B raises joins PTC board - Stock Titan
SG Americas Securities LLC Has $67.94 Million Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Gains Attention After Rating Updates - Kalkine Media
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Assessing PTC Therapeutics (PTCT) Valuation As Rare Disease Growth And Sephience Execution Shape Expectations - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeut - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
PTC Therapeutics or Eli Lilly: Which Stock Has More Upside? - Trefis
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
Fundamentals Check: How sensitive is PTC Therapeutics Inc to inflationPortfolio Return Report & Accurate Intraday Trading Signals - baoquankhu1.vn
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Cinctive Capital Management LP Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Boxer Capital Management LLC Invests $12.27 Million in PTC Therapeutics, Inc. $PTCT - MarketBeat
What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative - simplywall.st
Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (PTCT) CEO logs RSU vesting and automatic tax share sale - Stock Titan
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
FDA Shift Reframes PTC Therapeutics Regulatory Risks And Reward Profile - Sahm
Insider Sell: Stephanie Okey Sells 15,167 Shares of PTC Therapeu - GuruFocus
Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics Director Sells Over $1 Million in Company Stock - TradingView
PTC Therapeutics (PTCT) director exercises options, sells 15,167 shares - Stock Titan
PTCT (NASDAQ: PTCT) insider reports proposed 2,662-share sale - Stock Titan
B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
FDA ‘blacklist’ in DMD? Legislator slams PTC turndown - bioworld.com
PTC Therapeutics at Barclays Conference: Sephience’s Global Potential By Investing.com - Investing.com Canada
PTCT: Sepiapterin’s rapid PKU launch drives strong growth, with global expansion and pipeline progress - TradingView
PTCT Earnings History & Surprises | EPS & Revenue Results | PTC THERAPEUTICS INC (NASDAQ:PTCT) - ChartMill
PTC Therapeutics Stock Soars 8.88%, Hits Intraday High of $69.17 - Markets Mojo
PTC Therapeutics at Leerink Conference: Strategic Growth in PKU Market By Investing.com - Investing.com Canada
Proposed sale: 15,167 PTCT shares listed by Fidelity (PTCT) - Stock Titan
PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally - Trefis
(PTCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Stephanie Okey Sells 6,333 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Neil Gregory Almstead Sells 3,989 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ: PTCT) director sells 6,333 shares at $63.38 - Stock Titan
Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer - Stock Titan
PTC Therapeutics (PTCT) CTO spouse sells shares under 10b5-1 trading plan - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9%Time to Buy? - MarketBeat
Jefferies Financial Group Acquires Stake in PTC Therapeutics - National Today
Jefferies Financial Group Inc. Acquires Shares of 1,584,678 PTC Therapeutics, Inc. $PTCT - MarketBeat
Ideas Watch: Will PTC Therapeutics Inc. benefit from government policy2026 Setups & Safe Entry Trade Signal Reports - baoquankhu1.vn
Dividend Watch: Is PTC Therapeutics Inc a stock for growth or value investorsMarket Volume Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):